Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jun 2021 | FROM AKERO THERAPEUTICS

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

Dec 2020 | From Akero Therapeutics

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.